Today's Pre-Market Stock Movers: PEP, MRNA, BGNE, CCJ and More
Gapping up
In reaction to earnings/guidance:
Other news:
• $El Pollo Loco(LOCO.US$ +12.7% (declares $1.50/sh special div; also authorizes new $20 mln share repurchase program)
• $KnowBe4(KNBE.US$ +11.4% (KnowBe4 is close to a deal to be acquired by Vista Equity Partners according to WSJ)
• $Autolus Therapeutics(AUTL.US$ +9.1% (announces that Moderna has exercised its option to license Autolus’ proprietary binders against an undisclosed immuno-oncology target for the development and commercialization of mRNA therapeutics)
• $Rocket Pharmaceuticals(RCKT.US$ +4.5% (Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy)
• $Sangamo Therapeutics(SGMO.US$ +4.2% (Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Nine Patients)
• $Moderna(MRNA.US$+3% (Moderna & Merck (MRK) announce exercise of option by Merck for joint development and commercialization of investigational personalized cancer vaccine)
• $ATAI Life Sciences(ATAI.US$ +3% (positive initial results for phase 1 trial of KUR-101 an oral formulation of mitragynine for OUD)
• $BeiGene(BGNE.US$ +2.3% (announces positive topline results from final progression-free survival analysis of BRUKINSA (zanubrutinib) Compared to IMBRUVICA (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia Trial)
Gapping down
In reaction to earnings/guidance:
Other news:
• $Cameco(CCJ.US$ -12.4% (CCJ and BEP form partnership to acquire Westinghouse Electric; also announces $650M bought deal offering; also provides Q3 operating update)
• $Eagle Pharmaceuticals(EGRX.US$ -1.3% (files $200 mln mixed securities shelf offering; also submitted an investigational new drug application to the FDA for CAL02 for the treatment of severe community-acquired bacterial pneumonia)
Disclaimer: Moomoo Technologies Inc. is providing this content for information and educational use only.
Read more
Comment
Sign in to post a comment